Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | Golda Meir 7 NESS-ZIONA 7403650 |
Tel: | N/A |
Website: | www.sol-gel.com |
IR: | See website |
Key People | ||
Moshe Arkin Executive Chairman of the Board | Alon Seri-Levy Chief Executive Officer, Co-Founder, Director | Gilad Mamlok Chief Financial Officer |
Itzik Yosef Vice President - Operations | Nissim Bilman Vice President - Quality | Ofra Levy-Hacham Vice President - Clinical and Regulatory Affairs |
Karine Neimann Vice President - Projects and Planning, Chief Chemist | Dubi Zamir Vice President - Special Projects | Ofer Toledano Vice President - Research and Development |
Business Overview |
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company's offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin. |
Financial Overview |
For the three months ended 31 March 2024, Sol Gel Technologies Ltd revenues increased 55% to $466K. Net loss decreased 41% to $6.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects RESEARCH AND DEVELOPMENT EXPENSES decrease of 43% to $5.3M (expense), GENERAL AND ADMINISTRATIVE EXPENSES decrease of 7% to $1.8M (expense). |